Highlights in clinical autonomic neurosciences: Clinical update on multiple system atrophy

William P. Cheshire

Research output: Contribution to journalArticle

Abstract

Multiple system atrophy (MSA) may be the most feared of diseases affecting the autonomic nervous system. Accordingly, concerted efforts are underway to elucidate further its pathophysiology with the objective of discovering effective neuroprotective interventions that can slow or halt its progression. Although the epidemiology of MSA is sporadic rather than familial, recently reported associations with COQ2 and C9orf72 suggest that in some cases genetic factors may influence the risk of developing the disease. Research has also identified prion-like characteristics of the expansion of pathologic α-synuclein in the central nervous system. A large clinical trial of rifampicin, which disaggregates and inhibits the formation of α-synuclein fibrils, however, was clearly negative. Other research has shown the importance of recognizing and treating vocal cord paralysis, which is associated with adverse prognosis.

Original languageEnglish (US)
Pages (from-to)5-7
Number of pages3
JournalAutonomic Neuroscience: Basic and Clinical
Volume186
Issue numberC
DOIs
StatePublished - 2014

Fingerprint

Synucleins
Multiple System Atrophy
Neurosciences
Autonomic Nervous System Diseases
Vocal Cord Paralysis
Prions
Rifampin
Research
Epidemiology
Central Nervous System
Clinical Trials

Keywords

  • Apnea
  • Multiple system atrophy
  • Prion diseases
  • Synucleinopathy
  • Ubiquinone

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Endocrine and Autonomic Systems

Cite this

Highlights in clinical autonomic neurosciences : Clinical update on multiple system atrophy. / Cheshire, William P.

In: Autonomic Neuroscience: Basic and Clinical, Vol. 186, No. C, 2014, p. 5-7.

Research output: Contribution to journalArticle

@article{74ad647caae9451bb6cb8d986e87d25d,
title = "Highlights in clinical autonomic neurosciences: Clinical update on multiple system atrophy",
abstract = "Multiple system atrophy (MSA) may be the most feared of diseases affecting the autonomic nervous system. Accordingly, concerted efforts are underway to elucidate further its pathophysiology with the objective of discovering effective neuroprotective interventions that can slow or halt its progression. Although the epidemiology of MSA is sporadic rather than familial, recently reported associations with COQ2 and C9orf72 suggest that in some cases genetic factors may influence the risk of developing the disease. Research has also identified prion-like characteristics of the expansion of pathologic α-synuclein in the central nervous system. A large clinical trial of rifampicin, which disaggregates and inhibits the formation of α-synuclein fibrils, however, was clearly negative. Other research has shown the importance of recognizing and treating vocal cord paralysis, which is associated with adverse prognosis.",
keywords = "Apnea, Multiple system atrophy, Prion diseases, Synucleinopathy, Ubiquinone",
author = "Cheshire, {William P.}",
year = "2014",
doi = "10.1016/j.autneu.2014.08.005",
language = "English (US)",
volume = "186",
pages = "5--7",
journal = "Autonomic Neuroscience: Basic and Clinical",
issn = "1566-0702",
publisher = "Elsevier",
number = "C",

}

TY - JOUR

T1 - Highlights in clinical autonomic neurosciences

T2 - Clinical update on multiple system atrophy

AU - Cheshire, William P.

PY - 2014

Y1 - 2014

N2 - Multiple system atrophy (MSA) may be the most feared of diseases affecting the autonomic nervous system. Accordingly, concerted efforts are underway to elucidate further its pathophysiology with the objective of discovering effective neuroprotective interventions that can slow or halt its progression. Although the epidemiology of MSA is sporadic rather than familial, recently reported associations with COQ2 and C9orf72 suggest that in some cases genetic factors may influence the risk of developing the disease. Research has also identified prion-like characteristics of the expansion of pathologic α-synuclein in the central nervous system. A large clinical trial of rifampicin, which disaggregates and inhibits the formation of α-synuclein fibrils, however, was clearly negative. Other research has shown the importance of recognizing and treating vocal cord paralysis, which is associated with adverse prognosis.

AB - Multiple system atrophy (MSA) may be the most feared of diseases affecting the autonomic nervous system. Accordingly, concerted efforts are underway to elucidate further its pathophysiology with the objective of discovering effective neuroprotective interventions that can slow or halt its progression. Although the epidemiology of MSA is sporadic rather than familial, recently reported associations with COQ2 and C9orf72 suggest that in some cases genetic factors may influence the risk of developing the disease. Research has also identified prion-like characteristics of the expansion of pathologic α-synuclein in the central nervous system. A large clinical trial of rifampicin, which disaggregates and inhibits the formation of α-synuclein fibrils, however, was clearly negative. Other research has shown the importance of recognizing and treating vocal cord paralysis, which is associated with adverse prognosis.

KW - Apnea

KW - Multiple system atrophy

KW - Prion diseases

KW - Synucleinopathy

KW - Ubiquinone

UR - http://www.scopus.com/inward/record.url?scp=84927716293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927716293&partnerID=8YFLogxK

U2 - 10.1016/j.autneu.2014.08.005

DO - 10.1016/j.autneu.2014.08.005

M3 - Article

AN - SCOPUS:84927716293

VL - 186

SP - 5

EP - 7

JO - Autonomic Neuroscience: Basic and Clinical

JF - Autonomic Neuroscience: Basic and Clinical

SN - 1566-0702

IS - C

ER -